Search | Clinical Trials Finder

Conditions: Acute Myeloid Leukemia
Interventions: ASTX727, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: BMTP-11; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor
Interventions: Atezolizumab, GDC-0919; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Scottsdale, Arizona • Santa Monica, California • Aurora, Colorado + 6 more

Conditions: Pancreatic Cancer
Interventions: Pembrolizumab, Neoadjuvant Chemoradiation; Drug · Radiation
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 6
States / cities: Phoenix, Arizona • Hartford, Connecticut • Miami, Florida + 3 more

Conditions: Treatment of Type I Diabetes Mellitus.
Interventions: Biological; Biological
Lead sponsor: DiaVacs, Inc.; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Solid Tumors
Interventions: dovitinib, fulvestrant; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Las Vegas, Nevada • The Bronx, New York

Conditions: Glioblastoma
Interventions: [177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide, Radiotherapy; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: New York, New York • Pittsburgh, Pennsylvania • Houston, Texas + 1 more

Conditions: Refractory Solid Tumours, Relapsed Small Cell Lung Cancer (SCLC)
Interventions: AZD1775, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Denver, Colorado • Sarasota, Florida • New York, New York + 2 more

Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, X-Ray Imaging; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 9
States / cities: Bethesda, Maryland • New York, New York • The Bronx, New York + 3 more

Conditions: Neoplasm
Interventions: preladenant, pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Cutaneous Melanoma, Brain Metastases
Interventions: Defactinib, Avutometinib, Encorafenib; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Iowa City, Iowa • Salt Lake City, Utah

Conditions: Breast Cancer
Interventions: Tucatinib in Combination with Palbociclib and Letrozole; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Tucson, Arizona • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Cetuximab, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, Transoral Robotic Surgery, Tremelimumab; Biological · Procedure · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions: SYS6043; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 16
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 12 more

Conditions: Metastatic Melanoma
Interventions: IN10018, Cobimetinib, Atezolizumab; Drug · Biological
Lead sponsor: InxMed (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • New York, New York + 1 more

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: IPN01203; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Grand Rapids, Michigan • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Advanced HER2-positive Breast Cancer
Interventions: AUY922, Trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Opioid Use Disorder
Interventions: BI 1356225, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Los Alamitos, California • Los Angeles, California • Decatur, Georgia + 2 more

Conditions: Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Stage I Mycosis Fungoides, Stage II Mycosis Fungoides, Stage III Mycosis Fungoides
Interventions: Quality-of-Life Assessment, Objective Grading of Skin Findings; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Solid Tumor, Breast Cancer, Cancer of Head and Neck
Interventions: RO6874281, Trastuzumab, Cetuximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 5
States / cities: Tucson, Arizona • La Jolla, California • Greeley, Colorado + 2 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Biopsy, Echocardiography Test, Iadademstat, Multigated Acquisition Scan, Questionnaire Administration, Venetoclax; Drug · Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced/Metastatic Tumors
Interventions: Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 8
States / cities: Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 5 more

Search by objective public record fields.

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors